References
- Zipes DP, DiMarco JP, Jackman WM, et al. ACC/AHA Task Force Report:
Guidelines for Clinical Intracardiac Electrophysiological and Catheter
Ablation Procedures. J Am Coll Cardiol. 1995;26(2):555-573.
- D’Silva A, Wright M. Advances in imaging for atrial fibrillation
ablation. Radiol Res Pract. 2011;2011:714864.
- Tuttle RR, Mills J. Dobutamine: development of a new catecholamine to
selectively increase cardiac contractility. Circ Res. 1975;
36(1):185-196.
- Vanegas DI, Perez C de J, Montenegro J de J, et al. Dobutamine use for
arrhythmia induction during electrical programmed heart stimulation.
Rev Colomb Cardiol. 2006;12(7):479-483.
- Cossú SF, Rothman SA, Chmielewski IL, Hsia HH, Vogel RL, Miller JM,
Buxton AE. The effects of isoproterenol on the cardiac conduction
system: site-specific dose dependence. J Cardiovasc Electrophysiol.
1997 Aug;8(8):847-53. doi: 10.1111/j.1540-8167.1997.tb00845.x. PMID:
9261710.
- Knight BP. The rising costs of isoproterenol. EP Lab Dig. 2013
Mar;17(3).
- Khot UN, Vogan ED, Militello MA. Nitroprusside and Isoproterenol Use
after Major Price Increases. N Engl J Med. 2017 Aug 10;377(6):594-595.
doi: 10.1056/NEJMc1700244. PMID: 28792879.
- Cismaru G. Arrhythmia induction in the EP lab. 1sted. Cham, Switzerland: Springer Nature Switzerland AG;2019:71-86.
- Gianni C, Sanchez JE, Mohanty S, Trivedi C, Della Rocca DG, Al-Ahmad
A, Burkhardt JD, Gallinghouse GJ, Hranitzky PM, Horton RP, Di Biase L,
Natale A. High-Dose Dobutamine for Inducibility of Atrial Arrhythmias
During Atrial Fibrillation Ablation. JACC Clin Electrophysiol. 2020
Dec 14;6(13):1701-1710. doi: 10.1016/j.jacep.2020.07.018. Epub 2020
Sep 30. PMID: 33334450.
- Piérard LA, Berthe C, Albert A, Carlier J, Kulbertus HE. Haemodynamic
alterations during ischaemia induced by dobutamine stress testing. Eur
Heart J. 1989 Sep;10(9):783-90. doi:
10.1093/oxfordjournals.eurheartj.a059571. PMID: 2806276.
- Lu D, Greenberg MD, Little R, Malik Q, Fernicola DJ, Weissman NJ.
Accelerated dobutamine stress testing: safety and feasibility in
patients with known or suspected coronary artery disease. Clin
Cardiol. 2001 Feb;24(2):141-5. doi: 10.1002/clc.4960240208. PMID:
11214744; PMCID: PMC6654775.
- Mazeika PK, Nadazdin A, Oakley CM. Dobutamine stress echocardiography
for detection and assessment of coronary artery disease. J Am Coll
Cardiol. 1992 May;19(6):1203-11. doi: 10.1016/0735-1097(92)90325-h.
PMID: 1564221.
- Burger AJ, Notarianni MP, Aronson D. Safety and efficacy of an
accelerated dobutamine stress echocardiography protocol in the
evaluation of coronary artery disease. Am J Cardiol. 2000 Oct
15;86(8):825-9. doi: 10.1016/s0002-9149(00)01100-0. PMID: 11024395.
- Masoni A, Alboni P, Malacarne C, Codeca L. Effects of dobutamine on
electrophysiological properties of the specialized conduction system
in man. J Electrocardiol. 1979 Oct;12(4):361-70. doi:
10.1016/s0022-0736(79)80004-7. PMID: 512532.
- Hariman, Robert J, Gomes, Joseph, El-Sharif, N.
Catecholamine-dependent Atrioventricular Nodal Reentrant Tachycardia.
Circulation 1983;67(3):1983.
Figure Legends.
Figure 1. Demonstrates the relative decrease in sinus cycle length from
baseline to 5 mcg/kg/min, 10 mcg/kg/min, 15 mcg/kg/min and 20 mcg/kg/min
of dobutamine.
Figure 2. Demonstrates the relative decrease in AVNBCL and VABCL from
baseline to 5 mcg/kg/min, 10 mcg/kg/min, 15 mcg/kg/min and 20 mcg/kg/min
of dobutamine.
Figure 3. Demonstrates the relative decrease in AH interval from
baseline to 5 mcg/kg/min, 10 mcg/kg/min, 15 mcg/kg/min and 20 mcg/kg/min
of dobutamine.
Figure 4. Demonstrates the relative change in HV interval from baseline
to 5 mcg/kg/min, 10 mcg/kg/min, 15 mcg/kg/min and 20 mcg/kg/min of
dobutamine.
Figure 5. Demonstrates the relative change in QRS duration and QT
interval from baseline to 5 mcg/kg/min, 10 mcg/kg/min, 15 mcg/kg/min and
20 mcg/kg/min of dobutamine.
Figure 6. Demonstrates the relative change in AERP, AVNERP and VERP from
baseline to 5 mcg/kg/min, 10 mcg/kg/min, 15 mcg/kg/min and 20 mcg/kg/min
of dobutamine.
Figure 7. Demonstrates the relative change in diastolic blood pressure
and systolic blood pressure from baseline to 5 mcg/kg/min, 10
mcg/kg/min, 15 mcg/kg/min and 20 mcg/kg/min of dobutamine.
Table 1. Patient Demographics and EP/Ablation Indications